Atlas Trials

Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

Clinical trial NCT05008237 · UNKNOWN

Trial details

NCT number
NCT05008237
Sponsor
Samsung Medical Center
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Salivary Gland Cancer
Start date
2014-05-02
Primary completion
2022-05-01
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.